Mosaic Financial Group LLC Has $2.05 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Mosaic Financial Group LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 30.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,308 shares of the company’s stock after selling 1,004 shares during the period. Eli Lilly and Company comprises about 1.5% of Mosaic Financial Group LLC’s investment portfolio, making the stock its 11th biggest holding. Mosaic Financial Group LLC’s holdings in Eli Lilly and Company were worth $2,045,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Dorsey Wright & Associates lifted its holdings in shares of Eli Lilly and Company by 1.5% during the 3rd quarter. Dorsey Wright & Associates now owns 18,733 shares of the company’s stock valued at $16,597,000 after buying an additional 271 shares during the last quarter. Dunhill Financial LLC raised its position in Eli Lilly and Company by 15.0% during the third quarter. Dunhill Financial LLC now owns 643 shares of the company’s stock valued at $570,000 after acquiring an additional 84 shares in the last quarter. MCIA Inc lifted its stake in Eli Lilly and Company by 6.7% in the third quarter. MCIA Inc now owns 254 shares of the company’s stock valued at $208,000 after acquiring an additional 16 shares during the last quarter. Main Management ETF Advisors LLC bought a new stake in Eli Lilly and Company in the third quarter worth approximately $687,000. Finally, Orion Portfolio Solutions LLC increased its stake in shares of Eli Lilly and Company by 2.2% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 38,242 shares of the company’s stock worth $33,880,000 after purchasing an additional 816 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $826.71 on Friday. The firm’s 50-day moving average is $842.70 and its 200-day moving average is $871.52. The company has a market cap of $784.81 billion, a price-to-earnings ratio of 89.37, a PEG ratio of 3.14 and a beta of 0.41. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. Eli Lilly and Company has a 52-week low of $561.65 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter in the prior year, the firm earned $0.10 earnings per share. The company’s revenue was up 20.4% on a year-over-year basis. Equities research analysts anticipate that Eli Lilly and Company will post 13.21 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.63%. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

Analysts Set New Price Targets

LLY has been the subject of several analyst reports. Wolfe Research started coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective for the company. Truist Financial boosted their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Barclays reduced their target price on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. Finally, Citigroup increased their price target on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a report on Friday, October 25th. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.